Privo Technologies, Inc. attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year due to COVID-19, Bio International 2021 was informative and enjoyable. The company connected with potential investors and industry partners in discussing their...
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment of Dr. James Mackay to Its Board of Directors. BOSTON, June 30, 2020 (Newswire.com) - Dr. Mackay joins the Board of Directors...
The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at promising early stage companies. Winners and runners-up receive cash prizes based on their presented cancer therapy concepts, breakthroughs, discoveries or...
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD) Grant program to further support the Phase II clinical study. Privo Technologies is one of 12 institutions in the US...
Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute (NIDCR) in Philadelphia.
Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its nano-engineered platform technology and its product PRV111 for oral cancer at two major events in Asia. In January 2019, Privo...
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR Bridge Award supports Privo's clinical trial for its nanotechnology-based treatment of oral cancer. This award was given to only 4 companies...
BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to begin patient recruitment for a prospective clinical trial (NCT03502148) targeting early-stage oral cavity squamous cell carcinoma (OCSCC). Privo is now actively...
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work...
- © UX Strategy & Digital Branding